

## Message Text

LIMITED OFFICIAL USE

PAGE 01 HONG K 13975 141655Z

ACTION EA-12

INFO OCT-01 ISO-00 SCS-06 CA-01 OES-07 /027 W

-----120777 141706Z /43

P R 140715Z NOV 77

FM AMCONSUL HONG KONG

TO SECSTATE WASHDC PRIORITY 7723

INFO USLO PEKING

LIMITED OFFICIAL USE HONG KONG 13975

STADIS//////////

DEPT FOR EA/PRCM

EO 11652: N/A

TAGS: CASC, SWEL, CH, HK, US

SUBJECT: U.S. CITIZEN INQUIRY ABOUT NEW PRC CANCER DRUG

REF: HONG KONG 13799

1. SUBSEQUENT DOUGALL-MARTIN CONVERSATIONS NOVEMBER 10,  
WE HAVE RECEIVED BROUCHURE ON "ANTICANCERLIN" AND ANOTHER  
DRUG CALLED "DECANCERLIN." TEXT OF BROCHURE AS FOLLOWS:

BEGIN QUOTE. ANTICANCERLIN (SUGAR-COATED TABLETS)

ANTICANCERLIN IS AN EFFECTIVE REMEDY RECENTLY DISCOVERED  
FOR THE TREATMENT OF MALIGNANT TUMORS. IT IS CAREFULLY  
EXTRACTED AND PRSPARED FROM SPECIAL CHINESE DRUG. IT CAN  
EXERT FAVOURABLE THERAPEUTIC EFFECT IN CANCERS. IT MAY  
BE GIVEN TO NEOPLASTIC PATIENTS AFTER SURGICAL OPERATION.  
IT HAS THE CHARACTERISTICS OF EVIDENT EFFICACY IN THE  
TREATMENT OF MALIGNANT TUMORS AND RARE SIDE-EFFECTS, AND  
IT IS SUITABLE FOR LONG-TERM ADMINISTRATION. IT IS  
DEEPLY WELCOME BY CARCINOMA PATIENTS AND MEDICAL

LIMITED OFFICIAL USE

LIMITED OFFICIAL USE

PAGE 02 HONG K 13975 141655Z

PERSONNEL AT HOME AND ABROAD.

ACTION AND EFFECTS;

AS PROVED BY EXTENSIVE EXPERIMENTS IN THE TREATMENT OF  
MALIGNANT TUMORS, ANTICANCERLIN CAN DIMINISH THE  
SIZE OF TUMORS AND IMPROVE THE SUBJECTIVE SYMPTOMS.

(AN INCREASE IN APPETITE, ALLEVIATION OF PAINS AND IMPROVEMENT IN STRENGTH HAVE BEEN OBSERVED IN CLINICAL PRACTICE.) IT CAN REDUCE THE POSSIBILITY OF COMPLICATIONS. IT CAN MAKE THE JAUNDICE CAUSED

BY SOME CANCER DISAPPEAR. ADMINISTRATION OF THIS DRUG IN LATE STAGE NEOPLASTIC PATIENTS CAN PROLONG THE DURATION OF REMISSION. AVERAGE REMISSION OVER ONE YEAR AND A HALF HAS BEEN REPORTED IN CASE OF ADVANCED PANCREATIC CANCER. FURTHERMORE, ONLY FEW SIDE-EFFECTS ARE ENCOUNTERED WITHIN LONG-TERM ADMINISTRATION. IN CLINICAL PRACTICE, REDUCTION IN WHITE CELLS OR PLATELETS AND LIVER DAMAGE HAVE NOT BEEN REPORTED, AND THERE ARE NO MARKED GASTROINTESTINAL REACTIONS SUCH AS NAUSEA, VOMITING AND DIARRHEA.

INDICATIONS:

ACCORDING TO THE ORDER OF EFFICACY OF THIS DRUG IN CLINICAL EXPERIMENTS, IT IS CHIEFLY INDICATED IN PANCREATIC, GASTRIC, RECTAL, HEPATIC AND ESOPHAGEAL CANCERS; AND IS ALSO USEFUL IN PULMONARY, URINARY BLADDER, NASOPHARYNGEAL, THYROID CANCERS AND LEUKEMIA.

LIMITED OFFICIAL USE

LIMITED OFFICIAL USE

PAGE 03 HONG K 13975 141655Z

ADMINISTRATION AND DOSAGE:

FOUR TABLETS EACH TIME, THREE TIMES A DAY, OR AS DIRECTED BY THE PHYSICIAN.

PACKING:

IN BOTTLES OF 100 TABLETS, EACH CONTAINING 0.25 GM OF ANTICANCERLIN EXTRACT.

STORAGE:

KEEP IN WELL-CLOSED BOTTLES AND STORE IN A COOL JTM DRY PLACE.

DECANCERLIN TABLETS:

THE DECANCERLIN TABLETS, AN ANTI-CANCER DRUG, WAS MADE AFTER SCRUPULOUS INVESTIGATIONS. IT IS EXTRACTED AND PREPARED FROM CHINESE HERBS AND ONE OF ITS MAJOR COMPONENTS IS SELAGINELLA DOEDERLEINII HIERON. IT HAS BEEN PROVEN CLINICALLY THAT IT IS EFFECTIVE

FOR TUMOURS THAT ARE RESPONSIVE TO CHEMICAL AND RADIATION THEREAPY. IT IS PARTICULARLY GOOD IN CASES OF SMALL TUMOURS. IN CONJUNCTION WITH OTHER ANTI-CANCER DRUGS AND RADIOTHERAPY, IT CAN SHORTEN THE COURSE OF TREATMENT AND OFTEN CAUSES TUMOUR REGRESSION. THIS METHOD OF TREATMENT IS MORE EFFECTIVE THAN USING EITHER CHEMOTHERAPY OR RADIOTHERAPY ALONE. IT IS VERY EFFECTIVE FOR TREATING CHORIONIC CARCINOMA AND LUNG METASTASES. THE PEAK OF ACTION RANGES FROM 15 TO 25 DAYS DURING THE COURSE OF TREATMENT. BESIDES, IT IS NON-TOXIC AND DOES NOT INHIBIT THE NORMAL FUNCTION OF BONE MARROW. IT HAS BEEN HIGHLY REGARDED BOTH WITHIN AND OUTSIDE THE COUNTRY.

LIMITED OFFICIAL USE

LIMITED OFFICIAL USE

PAGE 04 HONG K 13975 141655Z

HOWEVER, IT IS NOT VERY EFFECTIVE IN CASES OF FAST GROWING TUMOURS. IN A FEW CASES THE INDICATION IS THAT THE BODY BUILDS UP RESISTANCE TO THE DRUG AFTER PROLONGED USAGE.

SCOPE OF APPLICATION:

MAINLY IN CHORIOEPITHELIOMA AND IN CANCERS OF THE UTERUS, NASOPHARYNX, LUNGS, PHARYNX AND OF THE STOMACH. IT IS ALSO ACTIVE IN OTHER CARCINOMAS.

DOSAGE:

ORAL, 7 TABLETS/TIME, 3 TIMES/DAY.

PACKAGE:

100 TABLETS/BOTTLE, 0.5 GM/TABLET.

STORAGE:

STORE IN A COOL PLACE MUST BE KEPT PROPERLY SEALED.

END QUOTE.

2. PLEASE PASS ABOVE TO MR. SPEYER. DR. CHENG ALSO ADVISES HE WOULD BE HAPPY TO TALK WITH MR. SPEYER, BUT ADDS HE HAS LITTLE EXPERIENCE WITH THE DRUG. AS NOTED REFTEL, DR. CHENG'S PHONE NUMBER IS 3-841-111.  
SHOESMITH

LIMITED OFFICIAL USE

NNN

## Message Attributes

**Automatic Decaptoning:** Z  
**Capture Date:** 01-Jan-1994 12:00:00 am  
**Channel Indicators:** n/a  
**Current Classification:** UNCLASSIFIED  
**Concepts:** DRUGS, CANCER  
**Control Number:** n/a  
**Copy:** SINGLE  
**Sent Date:** 14-Nov-1977 12:00:00 am  
**Decaption Date:** 22 May 2009  
**Decaption Note:** 25 YEAR REVIEW  
**Disposition Action:** RELEASED  
**Disposition Approved on Date:**  
**Disposition Case Number:** n/a  
**Disposition Comment:** 25 YEAR REVIEW  
**Disposition Date:** 22 May 2009  
**Disposition Event:**  
**Disposition History:** n/a  
**Disposition Reason:**  
**Disposition Remarks:**  
**Document Number:** 1977HONGK13975  
**Document Source:** CORE  
**Document Unique ID:** 00  
**Drafter:** n/a  
**Enclosure:** n/a  
**Executive Order:** N/A  
**Errors:** N/A  
**Expiration:**  
**Film Number:** D770420-1165  
**Format:** TEL  
**From:** HONG KONG  
**Handling Restrictions:**  
**Image Path:**  
**ISecure:** 1  
**Legacy Key:** link1977/newtext/t19771163/aaaacbxu.tel  
**Line Count:** 166  
**Litigation Code IDs:**  
**Litigation Codes:**  
**Litigation History:**  
**Locator:** TEXT ON-LINE, ON MICROFILM  
**Message ID:** 3deff31a-c288-dd11-92da-001cc4696bcc  
**Office:** ACTION EA  
**Original Classification:** LIMITED OFFICIAL USE  
**Original Handling Restrictions:** STADIS  
**Original Previous Classification:** n/a  
**Original Previous Handling Restrictions:** n/a  
**Page Count:** 4  
**Previous Channel Indicators:** n/a  
**Previous Classification:** LIMITED OFFICIAL USE  
**Previous Handling Restrictions:** STADIS  
**Reference:** 77 HONG KONG 13799  
**Retention:** 0  
**Review Action:** RELEASED, APPROVED  
**Review Content Flags:**  
**Review Date:** 10-Jan-2005 12:00:00 am  
**Review Event:**  
**Review Exemptions:** n/a  
**Review Media Identifier:**  
**Review Release Date:** n/a  
**Review Release Event:** n/a  
**Review Transfer Date:**  
**Review Withdrawn Fields:** n/a  
**SAS ID:** 604686  
**Secure:** OPEN  
**Status:** NATIVE  
**Subject:** U.S. CITIZEN INQUIRY ABOUT NEW PRC CANCER DRUG  
**TAGS:** CASC, SWEL, CH, HK, US  
**To:** STATE  
**Type:** TE  
**vdkvgwkey:** odbc://SAS/SAS.dbo.SAS\_Docs/3deff31a-c288-dd11-92da-001cc4696bcc  
**Review Markings:**  
Margaret P. Grafeld  
Declassified/Released  
US Department of State  
EO Systematic Review  
22 May 2009  
**Markings:** Margaret P. Grafeld Declassified/Released US Department of State EO Systematic Review 22 May 2009